Improvement in Hidradenitis Suppurativa and Quality of Life in Patients Treated With Adalimumab: Real-World Results From the HARMONY Study

Acne

Evidence for a "window of opportunity" in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicenter cohort study

Br J Dermatol.

Marzano AV, Genovese G, Casazza G, Moltrasio C, Dapavo P, Micali G, Sirna R, Gisondi P, Patrizi A, Dini V, Bianchini D, Bianchi L, Fania L, Prignano F, Offidani A, Atzori L, Bettoli V, Cannavò SP, Venturini M, Bongiorno MR, Costanzo A, Fabbrocini G, Peris K

doi: 10.1111/bjd.18983.

Acne

Real-world effectiveness of adalimumab in patients with moderate to severe hidradenitis suppurativa: The 1-year SOLACE study

J Eur Acad Dermatol Venereol

Gulliver W, Alavi A, Wiseman MC, Gooderham MJ, Rao J, Alam MS, Papp KA, Desjardins O, Jean C

doi: 10.1111/jdv.17598

Psoriasis

Characteristics and Outcomes of Patients Treated With Apremilast in the Real World: Results From the APPRECIATE Study

J Eur Acad Dermatol Venereol.

Augustin M, Kleyn CE, Conrad C, Sator PG, Ståhle M, Eyerich K, Radtke MA, Bundy C, Mellars L, Greggio C, Cordey M, Koscielny V, Griffiths CEM

doi: 10.1111/jdv.16431.

AcneRosacea

Quality of life measurement in hidradenitis suppurativa: position statement of the European Academy of Dermatology and Venereology task forces on Quality of Life and Patient-Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa

J Eur Acad Dermatol Venereol.

Chernyshov PV, Zouboulis CC, Tomas-Aragones L, Jemec GB, Svensson A, Manolache L, Tzellos T, Sampogna F, Pustisek N, van der Zee HH, Marron SE, Spillekom-van Koulil S, Bewley A, Linder D, Abeni D, Szepietowski JC, Augustin M, Finlay AY

doi: 10.1111/jdv.15519.

Acne

Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study

J Am Acad Dermatol.

Zouboulis CC, Okun MM, Prens EP, Gniadecki R, Foley PA, Lynde C, Weisman J, Gu Y, Williams DA, Jemec GBE

doi: 10.1016/j.jaad.2018.05.040.

Psoriatic Arthritis

Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study

Arthritis Res Ther.

Coates LC, Gladman DD, Nash P, FitzGerald O, Kavanaugh A, Kvien TK, Gossec L, Strand V, Rasouliyan L, Pricop L, Ding K, Jugl SM, Gaillez C; FUTURE 2 study group

doi: 10.1186/s13075-018-1773-y.

Atopic Dermatitis

Dupilumab treatment improves quality of life in adult patients with moderate-to-severe atopic dermatitis: Results from a randomized, placebo-controlled clinical trial

Br J Dermatol.

Tsianakas A, Luger TA, Radin A

doi: 10.1111/bjd.15905.

COMMENTED

Psoriasis

Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies

Am J Clin Dermatol.

Armstrong AW, Reich K, Foley P, Han C, Song M, Shen YK, You Y, Papp KA

doi: 10.1007/s40257-018-0396-z.

AcnePsoriasis

Five-year maintenance of clinical response and improvements in health-related quality of life in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2

Br J Dermatol

Reich K, Gordon KB, Strober BE, Armstrong AW, Miller M, Shen YK, You Y, Han C, Yang YW, Foley P, Griffiths CEM

doi: 10.1111/bjd.20568

Related content

Evidence for a "window of opportunity" in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicenter cohort study

Real-world effectiveness of adalimumab in patients with moderate to severe hidradenitis suppurativa: The 1-year SOLACE study

Characteristics and Outcomes of Patients Treated With Apremilast in the Real World: Results From the APPRECIATE Study

Quality of life measurement in hidradenitis suppurativa: position statement of the European Academy of Dermatology and Venereology task forces on Quality of Life and Patient-Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa

Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study

Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study

Dupilumab treatment improves quality of life in adult patients with moderate-to-severe atopic dermatitis: Results from a randomized, placebo-controlled clinical trial

Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies

Five-year maintenance of clinical response and improvements in health-related quality of life in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2